Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1115241 | 0.87 | MAPT (0.51) | MAPTALDH1A1L3MBTL1GAAMGAM | |
| SCHEMBL29186053 | 0.87 | MAPT (0.51) | MAPTALDH1A1L3MBTL1GAAMGAM | |
| SCHEMBL29186066 | 0.85 | MAPT (0.49) | MAPTALDH1A1L3MBTL1GAAMGAM | |
| SCHEMBL29186055 | 0.82 | MAPT (0.45) | MAPTALDH1A1L3MBTL1GAAMGAM | |
| SCHEMBL13613119 | 0.80 | MAPT (0.50) | MAPTALDH1A1L3MBTL1NPSR1CYP4F2 | |
| SCHEMBL7434611 | 0.79 | MAPT (0.41) | MAPTALDH1A1L3MBTL1GAAMGAM | |
| SCHEMBL10890944 | 0.79 | MAPT (0.38) | MAPTALDH1A1L3MBTL1GAAMGAM | |
| SCHEMBL11186364 | 0.79 | GAA (0.47) | MAPTALDH1A1GAAMGAMSI | |
| SCHEMBL28350168 | 0.78 | MAPT (0.40) | MAPTALDH1A1L3MBTL1GAAMGAM | |
| SCHEMBL7445187 | 0.78 | GAA (0.41) | MAPTALDH1A1L3MBTL1GAAMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092799-A1 | MNK INHIBITORS | HEPAGENE THERAPEUTICS HK LTD (CN) | 2024-03-21 | — | — | US | disclosed |
| CN-116490505-A | MNK inhibitors | 和博医药有限公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-4200296-A1 | MNK INHIBITORS | Hepagene Therapeutics (HK) Limited (HK) | 2023-06-28 | — | — | EP | disclosed |
| WO-2022038563-A1 | MNK INHIBITORS | Hepagene Therapeutics (HK) Limited (CN) | 2022-02-24 | — | — | WO | disclosed |
| US-20090203694-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | HURLEY TIMOTHY BRIAN | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092799-A1 | MNK INHIBITORS | MKNK1, MATK, NEK1 | MAPT 2458/4885ALDH1A1 4526/4885L3MBTL1 1524/4885 |
| US-20090203694-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | FDPS, UMPS, GGPS1 | MAPT 1345/4885ALDH1A1 3119/4885L3MBTL1 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.